Recombinant serotype 5 (Ad5) adenoviral vectors
The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.
1. A recombinant serotype 5 (Ad5) adenovirus comprising:
a) a nucleic acid sequence encoding an E2F-1 promoter replacing the natural E1A adenoviral promoter;
b) at least a 24 bp deletion (D24) in the Rb binding constant region 2 of E1;
c) at least a deletion in gp19k/6.7K in E3; and
d) a nucleic acid sequence encoding an immunostimulatory transgene inserted in the deletion in gp19k/6.7K.
2. The recombinant Ad5 adenovirus according to claim 1 , further comprising a capsid modification.
3. The recombinant Ad5 adenovirus according to claim 2 , wherein the capsid modification is a substitution wherein a region encoding Ad5 adenoviral fiber knob is replaced by the corresponding region from another adenovirus serotype.
4. The recombinant Ad5 adenovirus according to claim 1 , further comprising a nucleic acid element which activates TLR9 comprising a CpG island inserted in an E3 region downstream of the immunostimulatory transgene.
5. The recombinant Ad5 adenovirus according to claim 2 , wherein when the recombinant Ad5 adenovirus fiber knob region comprises Ad5 adenoviral fiber knob the adenovirus genome further comprises an RGD motif (Arg-Gly-Asp) inserted in the HI loop of the adenoviral fiber knob.
6. The recombinant Ad5 adenovirus according to claim 2 , wherein when the recombinant Ad5 adenovirus fiber knob region comprises Ad5 adenoviral fiber knob the adenovirus genome comprises a polylysine motif introduced in the C terminus of the adenovirus fiber knob.
7. The recombinant Ad5 adenovirus according to claim 2 , wherein when the recombinant Ad5 adenovirus fiber knob region comprises Ad3 adenoviral fiber knob, the nucleic acid modification in a fiber shaft region comprises a GAGA (SEQ ID NO: 28) motif substituted for the KKTK (SEQ ID NO: 29) motif.
8. The recombinant Ad5 adenovirus according to claim 1 , wherein the virus genome further comprises at least one element selected from the group consisting of adenoviral immediate early genes, intermediate genes, and late genes.
9. A method of treating a cancer comprising administering to a subject suffering from the cancer the recombinant Ad5 adenovirus of claim 1 , thereby treating the cancer.
10. A recombinant Ad5 adenovirus comprising the nucleic acid sequence according to SEQ ID NO: 1, 2, 3, 4, 5, 6, or 7.
11. A method of producing and recovering infectious recombinant Ad5 adenovirus articles comprising the steps of
a) providing a recombinant Ad5 adenovirus comprising
i) a nucleic acid sequence encoding an E2F-1 promoter replacing the natural EIA adenoviral promoter;
ii) at least a 24 bp deletion (D24) in the Rb binding constant region 2 of E1;
iii) at least a deletion in gp19k/6.7K in E3; and
iv) a nucleic acid sequence encoding an immunostimulatory transgene inserted in the deletion in gp19k/6.7K,
b) culturing the host cell under conditions allowing said recombinant Ad5 adenovirus to propagate and to produce infectious recombinant Ad5 adenovirus particles, and
c) recovering said infectious recombinant Ad5 adenovirus particles.
12. A pharmaceutical composition comprising the recombinant Ad5 adenovirus according to claim 1 and a pharmaceutically acceptable carrier.
13. A virus particle comprising the recombinant Ad5 adenovirus according to claim 1 .
14. An isolated host cell comprising the recombinant Ad5 adenovirus according to claim 1 .
15. A method for inducing immunity directed against a cancer or treating a tumor in a subject comprising administering to the subject the recombinant Ad5 adenovirus of claim 1 , wherein the immunostimulatory transgene encodes a tumor specific antigen that is expressed, and thereby induces immunity directed against the cancer or treating the tumor.
16. The method of claim 9 comprising administering the recombinant Ad5 adenovirus several times.
17. A method of treating a cancer comprising sequentially administering recombinant Ad5 adenoviruses, each adenovirus comprising:
a) a nucleic acid sequence encoding E2F-1 promoter replacing the natural EIA adenoviral promoter;
b) at least a 24 bp deletion (D24) in the Rb binding constant region 2 of E1;
c) at least a deletion in gp19k/6.7K in E3;
d) a nucleic acid sequence encoding an immunostimulatory transgene inserted in the deletion in gp19k/6.7K; and
e) a nucleic acid element which activates TLR9 comprising a CpG island inserted in an E3 region downstream of the immunostimulatory transgene;
wherein to avoid neutralizing antibodies in a subject a subsequent administration comprises a recombinant Ad5 adenovirus having a different fiber knob of the capsid compared to the recombinant Ad5 adenovirus used in the first administration, thereby treating the cancer.
18. The method of claim 17 comprising one or several administrations of the recombinant Ad5 serotype adenovirus and radiotherapy, surgery, or administering one or more agent selected from the group consisting of a virus sensitizer, chemotherapeutic agent, verapamil, calcium channel blocker, anti-CD20 therapy, and autophagy inducing agent.
19. The recombinant Ad5 adenovirus according to claim 3 , wherein the other adenovirus serotype is Ad3.
20. The method of claim 1 , wherein the immunostimulatory transgene is hGM-CSF.
21. A method of treating a cancer comprising administering to a subject, at the site of the cancer, the recombinant Ad5 adenovirus of claim 10 , thereby treating the cancer.
22. The method of claim 21 comprising administering the recombinant Ad5 adenovirus several times.
23. The method of claim 21 comprising administering the recombinant Ad5 adenovirus several times, wherein to avoid neutralizing antibodies in a subject a subsequent administration comprises a recombinant Ad5 adenovirus having a different fiber knob of the capsid compared to the recombinant Ad5 adenovirus used in the first administration.
24. The method of claim 21 comprising one or several administrations of the recombinant Ad5 serotype adenovirus and radiotherapy, surgery, or administering one or more agent selected from the group consisting of a virus sensitizer, chemotherapeutic agent, verapamil, calcium channel blocker, anti-CD20 therapy, and autophagy inducing agent.
25. A method of producing and recovering infectious recombinant Ad5 adenovirus particles comprising the steps of
a) providing a recombinant adenovirus comprising the nucleic acid sequence according to SEQ ID NO: 1, 2, 3, 4, 5, 6, or 7 inside a host cell permissive for adenovirus replication,
b) culturing the host cell under conditions allowing said recombinant Ad5 adenovirus to propagate and to produce infectious recombinant Ad5 adenovirus particles, and
c) recovering said infectious recombinant Ad5 adenovirus particles.
26. A pharmaceutical composition comprising the recombinant Ad5 adenovirus according to claim 10 and a pharmaceutically acceptable carrier.
27. A virus particle comprising the recombinant Ad5 adenovirus according to claim 10 .
28. An isolated host cell comprising the recombinant Ad5 adenovirus according to claim 10 .
29. A method for inducing immunity directed against a cancer or treating a tumor in a subject comprising administering to the subject the recombinant Ad5 adenovirus of claim 10 , thereby inducing immunity directed against the cancer or treating the tumor.